If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today

Few would dispute that Pfizer (NYSE: PFE) is an icon within the pharmaceutical world. And, giving credit where it's due, the drugmaker largely led the charge against the COVID-19 pandemic with both a vaccine and treatment.

Anyone keeping tabs on this ticker of late, however, likely knows it's also been a disappointment since its contagion-driven peak. Indeed, thanks to more than a 60% pullback from its late-2021 high, investors that committed $10,000 to a position in Pfizer 10 years ago -- when its anti-cholesterol drug Lipitor, arthritis-fighting Enbrel, pneumonia vaccine Prevnar, and nerve pain and epilepsy treatment Lyrica were still firing on all cylinders -- would now be holding just a little over $7,000 worth of this pharmaceutical stock.

Things get measurably better when factoring in any reinvested dividends paid in the meantime, though, as the chart below illustrates. The position becomes a net winner, in fact, albeit a small one. All told, reinvesting all the dividends in more shares of this stock as they were paid would leave you with just a tad over $10,600 for the 10-year time frame, although this still trails the broad market's total returns for this stretch by a country mile.

Continue reading